{
    "id": 60318,
    "name": "acute promyelocytic leukemia",
    "source": "DOID",
    "definition": "An acute myeloid leukemia characterized by accumulation of promyelocytes in the bone marrow and by a translocation between chromosomes 15 and 17. [url:http\\://en.wikipedia.org/wiki/Acute_promyelocytic_leukemia, url:http\\://ghr.nlm.nih.gov/condition/acute-promyelocytic-leukemia]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:0060318",
    "evidence": [
        {
            "id": 4389,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In clinical studies that supported FDA approval, treatment with Tretinoin in acute promyelocytic leukemia patients harboring PML-RARA induced remission and resulted in improved survival when compared to chemotherapeutics (PMID: 8291820, PMID: 8712802, PMID: 1850498).",
            "molecularProfile": {
                "id": 2571,
                "profileName": "PML - RARA"
            },
            "therapy": {
                "id": 1877,
                "therapyName": "Tretinoin",
                "synonyms": null
            },
            "indication": {
                "id": 60318,
                "name": "acute promyelocytic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4511,
                    "pubMedId": 8291820,
                    "title": "All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/8291820"
                },
                {
                    "id": 4512,
                    "pubMedId": 1850498,
                    "title": "Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/1850498"
                },
                {
                    "id": 10792,
                    "pubMedId": 8712802,
                    "title": "Pathogenesis and management of acute promyelocytic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/8712802"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4722,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical trial that supported FDA approval, treatment with Trisenox (arsenic trioxide) resulted in complete remission in 85% (34/40) of acute promyelocytic leukemia patients harboring PML-RARA, with conversion to no detectable PML-RARA fusion in 86% of patients assessed by RT-PCR (PMID: 11559723).",
            "molecularProfile": {
                "id": 2571,
                "profileName": "PML - RARA"
            },
            "therapy": {
                "id": 640,
                "therapyName": "Arsenic trioxide",
                "synonyms": null
            },
            "indication": {
                "id": 60318,
                "name": "acute promyelocytic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10759,
                    "pubMedId": 11559723,
                    "title": "United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/11559723"
                },
                {
                    "id": 15572,
                    "pubMedId": null,
                    "title": "Trisenox (arsenic trioxide) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021248"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 5069,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PI-103 treatment inhibited proliferation and induced apoptosis in primary patient-derived acute promyelocytic leukemia cells with elevated Pik3cb and decreased Pik3ca protein expression in culture (PMID: 19176369).",
            "molecularProfile": {
                "id": 20234,
                "profileName": "PIK3CA dec exp PIK3CB over exp"
            },
            "therapy": {
                "id": 870,
                "therapyName": "PI-103",
                "synonyms": null
            },
            "indication": {
                "id": 60318,
                "name": "acute promyelocytic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4874,
                    "pubMedId": 19176369,
                    "title": "Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19176369"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5070,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY294002 inhibited proliferation of primary patient-derived acute promyelocytic leukemia cells with elevated Pik3cb and decreased Pik3ca protein expression in culture (PMID: 19176369).",
            "molecularProfile": {
                "id": 20234,
                "profileName": "PIK3CA dec exp PIK3CB over exp"
            },
            "therapy": {
                "id": 1062,
                "therapyName": "LY294002",
                "synonyms": null
            },
            "indication": {
                "id": 60318,
                "name": "acute promyelocytic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4874,
                    "pubMedId": 19176369,
                    "title": "Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19176369"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5071,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TGX-221 treatment inhibited proliferation and induced apoptosis in primary patient-derived acute promyelocytic leukemia cells with elevated Pik3cb and decreased Pik3ca protein expression in culture (PMID: 19176369).",
            "molecularProfile": {
                "id": 20234,
                "profileName": "PIK3CA dec exp PIK3CB over exp"
            },
            "therapy": {
                "id": 2514,
                "therapyName": "TGX-221",
                "synonyms": null
            },
            "indication": {
                "id": 60318,
                "name": "acute promyelocytic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4874,
                    "pubMedId": 19176369,
                    "title": "Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19176369"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5072,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, IC87114 inhibited proliferation and induced apoptosis in primary patient-derived acute promyelocytic leukemia cells with elevated Pik3cb and decreased Pik3ca protein expression in culture (PMID: 19176369).",
            "molecularProfile": {
                "id": 20234,
                "profileName": "PIK3CA dec exp PIK3CB over exp"
            },
            "therapy": {
                "id": 3504,
                "therapyName": "IC87114",
                "synonyms": null
            },
            "indication": {
                "id": 60318,
                "name": "acute promyelocytic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4874,
                    "pubMedId": 19176369,
                    "title": "Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19176369"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5073,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rapamune (sirolimus) inhibited proliferation and induced apoptosis in primary patient-derived acute promyelocytic leukemia cells with elevated Pik3cb and decreased Pik3ca protein expression in culture (PMID: 19176369).",
            "molecularProfile": {
                "id": 20234,
                "profileName": "PIK3CA dec exp PIK3CB over exp"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 60318,
                "name": "acute promyelocytic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4874,
                    "pubMedId": 19176369,
                    "title": "Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19176369"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5074,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TGX-155 moderately inhibited proliferation of acute promyelocytic leukemia cell lines expressing endogenous Pik3ca, Pik3cb, and Pik3cd in culture (PMID: 19176369).",
            "molecularProfile": {
                "id": 20238,
                "profileName": "PIK3CA pos PIK3CB pos PIK3CD pos"
            },
            "therapy": {
                "id": 3503,
                "therapyName": "TGX-155",
                "synonyms": null
            },
            "indication": {
                "id": 60318,
                "name": "acute promyelocytic leukemia",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4874,
                    "pubMedId": 19176369,
                    "title": "Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19176369"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5075,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PI-103 inhibited proliferation of acute promyelocytic leukemia cell lines expressing endogenous Pik3ca, Pik3cb, and Pik3cd in culture (PMID: 19176369).",
            "molecularProfile": {
                "id": 20238,
                "profileName": "PIK3CA pos PIK3CB pos PIK3CD pos"
            },
            "therapy": {
                "id": 870,
                "therapyName": "PI-103",
                "synonyms": null
            },
            "indication": {
                "id": 60318,
                "name": "acute promyelocytic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4874,
                    "pubMedId": 19176369,
                    "title": "Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19176369"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5076,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY294002 inhibited proliferation and induced apoptosis in acute promyelocytic leukemia cell lines expressing endogenous Pik3ca, Pik3cb, and Pik3cd in culture (PMID: 19176369).",
            "molecularProfile": {
                "id": 20238,
                "profileName": "PIK3CA pos PIK3CB pos PIK3CD pos"
            },
            "therapy": {
                "id": 1062,
                "therapyName": "LY294002",
                "synonyms": null
            },
            "indication": {
                "id": 60318,
                "name": "acute promyelocytic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4874,
                    "pubMedId": 19176369,
                    "title": "Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19176369"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5077,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, IC87114 moderately inhibited proliferation of acute promyelocytic leukemia cell lines expressing endogenous Pik3ca, Pik3cb, and Pik3cd in culture (PMID: 19176369).",
            "molecularProfile": {
                "id": 20238,
                "profileName": "PIK3CA pos PIK3CB pos PIK3CD pos"
            },
            "therapy": {
                "id": 3504,
                "therapyName": "IC87114",
                "synonyms": null
            },
            "indication": {
                "id": 60318,
                "name": "acute promyelocytic leukemia",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4874,
                    "pubMedId": 19176369,
                    "title": "Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19176369"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5078,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rapamune (sirolimus) moderately inhibited proliferation of acute promyelocytic leukemia cell lines expressing endogenous Pik3ca, Pik3cb, and Pik3cd in culture (PMID: 19176369).",
            "molecularProfile": {
                "id": 20238,
                "profileName": "PIK3CA pos PIK3CB pos PIK3CD pos"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 60318,
                "name": "acute promyelocytic leukemia",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4874,
                    "pubMedId": 19176369,
                    "title": "Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19176369"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5515,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In clinical case study, a patient with acute promyelocytic leukemia harboring PML-RARA treated with arsenic trioxide initially demonstrated a response, but subsequently developed resistance due to a secondary mutation, PML L218P (PMID: 21613260).",
            "molecularProfile": {
                "id": 20956,
                "profileName": "PML - RARA PML L218P"
            },
            "therapy": {
                "id": 640,
                "therapyName": "Arsenic trioxide",
                "synonyms": null
            },
            "indication": {
                "id": 60318,
                "name": "acute promyelocytic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 5077,
                    "pubMedId": 21613260,
                    "title": "Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21613260"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5516,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with acute promyelocytic leukemia harboring PML-RARA treated with arsenic trioxide initially demonstrated a response, but subsequently developed resistance due to a secondary mutation, PML A216V (PMID: 21613260).",
            "molecularProfile": {
                "id": 20957,
                "profileName": "PML - RARA PML A216V"
            },
            "therapy": {
                "id": 640,
                "therapyName": "Arsenic trioxide",
                "synonyms": null
            },
            "indication": {
                "id": 60318,
                "name": "acute promyelocytic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 5077,
                    "pubMedId": 21613260,
                    "title": "Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21613260"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7511,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, a 40.6 month follow-up of acute promyelocytic leukemia (APL) patients treated with the combination of Vesanoid (tretinoin) and Trisenox (arsenic trioxide) demonstrated a better event-free survival, cumulative incidence of relapse, and overall survival when compared to APL patients treated with the combination of Vesanoid (tretinoin) and chemotherapy (PMID: 27400939).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3687,
                "therapyName": "Arsenic trioxide + Tretinoin",
                "synonyms": null
            },
            "indication": {
                "id": 60318,
                "name": "acute promyelocytic leukemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6387,
                    "pubMedId": 27400939,
                    "title": "Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27400939"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7912,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with acute promyelocytic leukemia harboring BCOR-RARA demonstrated sensitivity to treatment with Vesanoid (tretinoin) and achieved a complete response (PMID: 25790901).",
            "molecularProfile": {
                "id": 24667,
                "profileName": "BCOR - RARA"
            },
            "therapy": {
                "id": 1877,
                "therapyName": "Tretinoin",
                "synonyms": null
            },
            "indication": {
                "id": 60318,
                "name": "acute promyelocytic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6523,
                    "pubMedId": 25790901,
                    "title": "Successful treatment of acute promyelocytic leukemia with a t(X;17)(p11.4;q21) and BCOR-RARA fusion gene.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25790901"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11375,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with acute promyelocytic leukemia harboring FLT3 D835Y demonstrated a complete molecular remission after treatment with Trisenox (arsenic trioxide) and Vesanoid (tretinoin) combined with Cytosar-U (cytarabine) and Methotrexate (PMID: 27626069).",
            "molecularProfile": {
                "id": 3153,
                "profileName": "FLT3 D835Y"
            },
            "therapy": {
                "id": 5965,
                "therapyName": "Arsenic trioxide + Cytarabine + Methotrexate + Tretinoin",
                "synonyms": null
            },
            "indication": {
                "id": 60318,
                "name": "acute promyelocytic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9268,
                    "pubMedId": 27626069,
                    "title": "Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27626069"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11376,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with acute promyelocytic leukemia developed meningeal relapse after maintenance therapy with Vesanoid (tretinoid), which was found to be due to a FLT3 D835Y variant (PMID: 27626069).",
            "molecularProfile": {
                "id": 3153,
                "profileName": "FLT3 D835Y"
            },
            "therapy": {
                "id": 1877,
                "therapyName": "Tretinoin",
                "synonyms": null
            },
            "indication": {
                "id": 60318,
                "name": "acute promyelocytic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9268,
                    "pubMedId": 27626069,
                    "title": "Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27626069"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11681,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EDO-S101 and Kyprolis (carfilzomib) worked synergistically to decrease viability of an acute promyelocytic leukemia cell line in culture (PMID: 28753594).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6106,
                "therapyName": "Carfilzomib + Tinostamustine",
                "synonyms": null
            },
            "indication": {
                "id": 60318,
                "name": "acute promyelocytic leukemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9700,
                    "pubMedId": 28753594,
                    "title": "The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28753594"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11685,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EDO-S101 and Velcade (bortezomib) worked synergistically to decrease viability of an acute promyelocytic leukemia cell line in culture (PMID: 28753594).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6105,
                "therapyName": "Bortezomib + Tinostamustine",
                "synonyms": null
            },
            "indication": {
                "id": 60318,
                "name": "acute promyelocytic leukemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9700,
                    "pubMedId": 28753594,
                    "title": "The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28753594"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13268,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Tretinoin (all-trans retinoic acid) treatment resulted in complete remission in a patient with acute promyelocytic leukemia harboring NUMA1-RARA (PMID: 9288109).",
            "molecularProfile": {
                "id": 29051,
                "profileName": "NUMA1 - RARA"
            },
            "therapy": {
                "id": 1877,
                "therapyName": "Tretinoin",
                "synonyms": null
            },
            "indication": {
                "id": 60318,
                "name": "acute promyelocytic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11031,
                    "pubMedId": 9288109,
                    "title": "Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/9288109"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18740,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, A-366 inhibited cell proliferation in an EHMT2-positive acute promyelocytic leukemia cell line in culture (PMID: 26147105).",
            "molecularProfile": {
                "id": 33565,
                "profileName": "EHMT2 positive"
            },
            "therapy": {
                "id": 8827,
                "therapyName": "A-366",
                "synonyms": null
            },
            "indication": {
                "id": 60318,
                "name": "acute promyelocytic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16422,
                    "pubMedId": 26147105,
                    "title": "The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26147105"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19569,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CD4CAR-expressing natural killer cells induced tumor cell lysis when co-cultured with a CD4-positive acute promyelocytic leukemia cell line in culture (PMID: 29348865).",
            "molecularProfile": {
                "id": 34220,
                "profileName": "CD4 positive"
            },
            "therapy": {
                "id": 9084,
                "therapyName": "CD4CAR",
                "synonyms": null
            },
            "indication": {
                "id": 60318,
                "name": "acute promyelocytic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17177,
                    "pubMedId": 29348865,
                    "title": "Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29348865"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20820,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a cell line xenograft model of acute promyelocytic leukemia expressing CD33 and consisting of human natural killer cells treated with GTB-3550 TriKE reduced tumor burden (PMID: 26847056).",
            "molecularProfile": {
                "id": 27618,
                "profileName": "CD33 positive"
            },
            "therapy": {
                "id": 9469,
                "therapyName": "GTB-3550 TriKE",
                "synonyms": null
            },
            "indication": {
                "id": 60318,
                "name": "acute promyelocytic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18074,
                    "pubMedId": 26847056,
                    "title": "IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26847056"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT01409161",
            "title": "Acute Promyelocytic Leukemia (APL) Treated With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3685,
                    "therapyName": "Arsenic trioxide + Gemtuzumab ozogamicin + Tretinoin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01869803",
            "title": "Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia",
            "phase": "Phase I",
            "recruitment": "Approved for marketing",
            "therapies": [
                {
                    "id": 756,
                    "therapyName": "Gemtuzumab ozogamicin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02339740",
            "title": "Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3686,
                    "therapyName": "Cytarabine + Dexamethasone + Idarubicin + Mitoxantrone",
                    "synonyms": null
                },
                {
                    "id": 3685,
                    "therapyName": "Arsenic trioxide + Gemtuzumab ozogamicin + Tretinoin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03674411",
            "title": "Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9613,
                    "therapyName": "Busulfan + Filgrastim + Fludarabine + Melphalan + MGTA-456 + Mycophenolate mofetil + Tacrolimus",
                    "synonyms": null
                },
                {
                    "id": 9612,
                    "therapyName": "Cyclophosphamide + Filgrastim + Fludarabine + MGTA-456 + Mycophenolate mofetil + Tacrolimus",
                    "synonyms": null
                }
            ]
        }
    ]
}